Sfoglia per RIVISTA
FUTURE ONCOLOGY (LONDON, ENGLAND)
Collezione AOU Novara
Items : 2
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. in Future oncology (London, England) / Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11.
2022
AOU Novara
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J;
FISH in triple-negative breast cancer: a possible strategy for the future? in Future oncology (London, England) / Future Oncol. 2015;11(7):1023-6. doi: 10.2217/fon.15.25.
2015
AOU Novara
Rigon E; Saggia C; Rossi V; Genestroni S; Gaudino E; Campisi P; Veggiani C; Boldorini RL; Alabiso O;